Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 2PIK3CA-Mutated Cancers 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 18Specimen Handling 17Magnetic Resonance Spectroscopy 12Biopsy 12Paclitaxel 9Carboplatin 8Radiosurgery 7Nivolumab 7trastuzumab deruxtecan 6Pemetrexed 6Leucovorin 6Irinotecan 6Fulvestrant 6Fluorouracil 6Bevacizumab 6palbociclib 5Oxaliplatin 5Letrozole 5Gemcitabine 5Cetuximab 5Taxes 4Cisplatin 4Capecitabine 4olaparib 3enzalutamide 3durvalumab 3Ipilimumab 3Docetaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × inavolisib × 30 days × Clear all
NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Genentech, Inc.

Phase 1 Active not recruiting
498 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡